321 reports of this reaction
1.4% of all DURVALUMAB reports
#16 most reported adverse reaction
COLITIS is the #16 most commonly reported adverse reaction for DURVALUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 321 FDA adverse event reports linking DURVALUMAB to COLITIS. This represents approximately 1.4% of all 23,251 adverse event reports for this drug.
Patients taking DURVALUMAB who experience colitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COLITIS is a less commonly reported adverse event for DURVALUMAB, but still significant enough to appear in the safety profile.
In addition to colitis, the following adverse reactions have been reported for DURVALUMAB:
The following drugs have also been linked to colitis in FDA adverse event reports:
COLITIS has been reported as an adverse event in 321 FDA reports for DURVALUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
COLITIS accounts for approximately 1.4% of all adverse event reports for DURVALUMAB, making it a notable side effect.
If you experience colitis while taking DURVALUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.